This acquisition establishes Boston Scientific as the leader in the treatment of BPH. With our innovative minimally invasive and laser therapies, Boston Scientific is the only urology partner to offer BPH solutions, education and clinical evidence to empower physicians to reach and effectively treat more patients at every stage of their journey.

But don’t just take our word for it. Watch this brief video featuring Kevin McVary, MD, FACS, Co-Chairman of the AUA BPH Clinical Guidelines Committee, the Co-Chairman of the International Consultation on Male LUTS and the Associate Editor of the Journal of Urology. He is currently and has recently been principal investigator for more than 75 clinical trials, including the Rezūm pivotal trial.

• Read the acquisition press release
• Learn more about the Rezūm System